Patents by Inventor Markku M. Jeltsch

Markku M. Jeltsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of VEGF-D gene to prevent restenosis
    Patent number: 8455453
    Abstract: The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: June 4, 2013
    Assignee: Vegenics Pty Ltd
    Inventors: Kari Alitalo, Seppo Ylä-Herttuala, Mikko O. Hiltunen, Markku M. Jeltsch, Marc G. Achen
  • Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
    Patent number: 8278098
    Abstract: The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: October 2, 2012
    Assignee: Vegenics Pty Limited
    Inventors: Kari Alitalo, Markku M. Jeltsch
  • MODIFIED VEGF-A WITH IMPROVED ANGIOGENIC PROPERTIES
    Publication number: 20120071406
    Abstract: The present invention is directed to methods and compositions for making and using chimeric polypeptides that comprise a VEGFR-2 ligand. The chimeric molecules of the present invention retain VEGFR-2 binding activity and an enhanced angiogenic activity as compared to native VEGF-A.
    Type: Application
    Filed: August 19, 2011
    Publication date: March 22, 2012
    Applicant: VEGENICS PTY LIMITED
    Inventors: KARI ALITALO, Tuomas Tammela, Salla Keskitalo, Katri Pajusola, Markku M. Jeltsch, Seppo Yla-Herttuala, Terhi Karpanen, Ulf Eriksson, Marko J. T. Uutela
  • Modified VEGF-A with improved angiogenic properties
    Patent number: 8025886
    Abstract: The present invention is directed to methods and compositions for making and using chimeric polypeptides that comprise a VEGFR-2 ligand. The chimeric molecules of the present invention retain VEGFR-2 binding activity and an enhanced angiogenic activity as compared to native VEGF-A.
    Type: Grant
    Filed: August 15, 2006
    Date of Patent: September 27, 2011
    Assignee: Vegenics Pty Ltd
    Inventors: Kari Alitalo, Tuomas Tammela, Salla Keskitalo, Katri Pajusola, Markku M. Jeltsch, Seppo Yla-Herttuala, Terhi Karpanen, Ulf Eriksson, Marko J. T. Uutela
  • Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
    Patent number: 7902149
    Abstract: The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: March 8, 2011
    Assignee: Vegenics Pty Limited
    Inventors: Kari Alitalo, Markku M. Jeltsch
  • Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
    Patent number: 7566566
    Abstract: The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: July 28, 2009
    Assignee: Vengenics Limited
    Inventors: Kari Alitalo, Markku M. Jeltsch
  • VEGFR-3 fusion proteins
    Patent number: 7422741
    Abstract: The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: September 9, 2008
    Assignee: Vegenics Limited
    Inventors: Kari Alitalo, Markku M. Jeltsch
  • Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
    Patent number: 7309604
    Abstract: The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: December 18, 2007
    Assignees: Licentia, Ltd., Ludwig Institute For Cancer Research
    Inventors: Kari Alitalo, Markku M. Jeltsch
  • Use of VEGF-C to prevent restenosis
    Patent number: 6958147
    Abstract: The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: October 25, 2005
    Assignees: Licentia Ltd, Seppo Yla-Herttuala, Ludwig Institute of Cancer Research
    Inventors: Kari Alitalo, Seppo Ylä-Herttuala, Mikko O. Hiltunen, Markku M. Jeltsch, Marc G. Achen